Alkermes (NASDAQ:[[ticker:ALKS]]), a Cambridge, MA-based biotech company, says that the FDA has asked the firm’s partner, Johnson & Johnson, for more information about a long-acting version of schizophrenia drug risperidone before the agency decides whether to approve it as supplemental treatment for bipolar disorder. The drug, marketed under the names Risperdal and Consta, garnered U.S. marketing approval in 2003 as a treatment for schizophrenia.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
